EGIS 6877
Latest Information Update: 15 Aug 2007
At a glance
- Originator Egis Pharmaceuticals
- Class Anxiolytics
- Mechanism of Action Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 07 Jul 1998 No-Development-Reported for Anxiety disorders in Hungary (PO)
- 05 Oct 1994 Preclinical development for Anxiety disorders in Hungary (PO)